KL1
Klotho fragment Β· Ξ±-Klotho KL1 domain Β· Klotho extracellular domain
The KL1 extracellular domain fragment of the anti-aging protein Ξ±-Klotho. A single peripheral injection of the KL1 fragment restored cognitive function in aged and ADHD mouse models, suggesting a systemic signaling role independent of FGF23 co-receptor activity.
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
Mechanism of Action
Ξ±-Klotho is a transmembrane protein shed as a circulating hormone that declines sharply with age. The KL1 domain appears to cross the blood-brain barrier or signal via peripheral pathways to enhance synaptic plasticity, upregulate GluN2B NMDA receptor subunits in the prefrontal cortex, and reduce oxidative stress. Circulating Klotho levels correlate positively with cognitive performance in humans.
Clinical Applications
- βCognitive aging and age-related memory decline (preclinical)
- βAttention and executive function research (preclinical)
- βNeuroprotection and synaptic plasticity enhancement (preclinical)
- βLongevity and healthspan extension research
- βPotential biomarker role: low Klotho as aging risk indicator
Dosing Protocol
Recommended Dosing
No human dosing established. Primate/mouse studies: single SC or IV injection of 10β250 Β΅g/kg produced cognitive effects lasting days to weeks. Human trials in planning stages. Not for clinical use.Safety & Contraindications
Possible Side Effects
- β Unknown safety profile in humans
- β Theoretical modulation of FGF23/phosphate metabolism with systemic Klotho elevation
- β Unknown cardiovascular effects at supraphysiological levels
Contraindications
- βAll human use outside approved clinical trials
- βChronic kidney disease (Klotho-FGF23 axis dysregulation)
- βPregnancy and breastfeeding